Title: A Phase III, Randomized, Double-blind, Placebo-controlled, Multi-center,
International Study of Durvalumab or Durvalumab and Tremelimumab as
Consolidation Treatment for Patients with Limited Stage Small Cell- Lung
Cancer Who Have Not Progressed Following Concurrent Chemoradiation
You are invited to take part in this research study because you have been diagnosed with a type of lung cancer - limited stage, small cell lung cancer (LS-SCLC), that cannot be removed by surgery. The reason for the study is to investigate effective consolidation treatment after standard concurrent chemotherapy and radiation therapy for this type of cancer.
Researchers have found that sometimes the body’s own immune system may slow down or control cancer growth. New drugs are being developed to increase the immune system response. Two such drugs are durvalumab and tremelimumab. AstraZeneca AB is doing this research to find out if the medications called durvalumab and tremelimumab will work, and be safe for the treatment of LS-SCLC.
Christopher Sumey, MD,Amit Panwalkar, MD